title: Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM.
abstract: The primary goal of the present study was to examine the effects of improved glycaemic control associated with glipizide treatment on postprandial lipaemia in non-insulin-dependent diabetic patients. The metabolism of triglyceride-rich lipoproteins of intestinal origin was assessed by measuring the retinyl palmitate content in plasma and the Svedberg flotation index (Sf) > 400 and Sf 20-400 lipoprotein fractions. Fasting plasma glucose concentrations (14.5 +/- 0.5 vs 9.0 +/- 0.5 mmol/l), glycated haemoglobin levels (13.1 +/- 0.6 vs. 9.7 +/- 0.6%), and daylong plasma glucose concentrations were all significantly lower after glipizide treatment (p < 0.001). The improvement in glycaemic control was associated with increases in insulin-mediated glucose uptake (p < 0.001) and plasma post-heparin lipoprotein and hepatic lipolytic activities (p < 0.02). Both fasting plasma triglyceride (3.09 +/- 0.51 vs 2.37 +/- 0.34 mmol/l), and postprandial triglyceride concentrations (p < 0.05-0.001) were lower following glipizide treatment, associated with a significant fall in retinyl palmitate content in all three lipoprotein fractions (p < 0.02-0.001), with the most substantial decrease seen in the Sf20-400 fraction. These data indicate that glipizide-induced improvement in glycaemic control was associated with changes in the metabolism of triglyceride-rich lipoproteins of intestinal origin that would be anticipated to reduce risk of coronary heart disease in non-insulin-dependent diabetic patients.
authors.affiliation: Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
authors.forename: J
authors.initials: J
authors.lastname: Jeppesen
authors.forename: M Y
authors.initials: MY
authors.lastname: Zhou
authors.forename: Y D
authors.initials: YD
authors.lastname: Chen
authors.forename: G M
authors.initials: GM
authors.lastname: Reaven
mesh_terms: D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood*; D002940:Circadian Rhythm; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D004224:Diterpenes; D004435:Eating; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D005260:Female; D005913:Glipizide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008049:Lipase / Q000097:blood; D008071:Lipoprotein Lipase / Q000097:blood; D008074:Lipoproteins / Q000097:blood*; D008099:Liver / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D000084562:Retinyl Esters; D014280:Triglycerides / Q000097:blood*; D014801:Vitamin A / Q000031:analogs & derivatives / Q000097:blood
chemical_list: D001786:Blood Glucose; D002784:Cholesterol; D004224:Diterpenes; D005230:Fatty Acids, Nonesterified; D005913:Glipizide; D006442:Glycated Hemoglobin; D008049:Lipase; D008071:Lipoprotein Lipase; D008074:Lipoproteins; D000084562:Retinyl Esters; D014280:Triglycerides; D014801:Vitamin A; C014794:retinol palmitate